Aquestive Therapeutics, Inc.
AQST
$4.06
$0.041.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.81% | -34.21% | -393.55% | -78.75% | -110.27% |
| Total Depreciation and Amortization | -8.24% | -12.58% | -31.71% | -32.85% | -65.59% |
| Total Amortization of Deferred Charges | 1.85% | 2.81% | 2.96% | 2.88% | 50.11% |
| Total Other Non-Cash Items | -44.01% | 71.15% | 49.02% | 1.30% | 22.05% |
| Change in Net Operating Assets | 262.13% | 40.44% | 110.99% | -143.75% | 580.36% |
| Cash from Operations | -30.51% | -6.47% | -12.96% | -125.35% | -31.30% |
| Capital Expenditure | -466.67% | -193.75% | -205.71% | -365.52% | 6.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -466.67% | -193.75% | -205.71% | -365.52% | 6.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 12.50% | -60.00% | -20.00% | 99.99% |
| Issuance of Common Stock | 306.55% | 42,121.76% | -- | -74.15% | -95.35% |
| Repurchase of Common Stock | -1,700.00% | 65.35% | -1,620.00% | 21.28% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -100.06% |
| Cash from Financing | 320.38% | 478,988.24% | -105.84% | -74.74% | -95.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.37% | 672.15% | -52.36% | -104.05% | -507.37% |